MX389724B - Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo - Google Patents
Compuestos de fenil-2-hidroxi-acetilamino-2-metil-feniloInfo
- Publication number
- MX389724B MX389724B MX2019012428A MX2019012428A MX389724B MX 389724 B MX389724 B MX 389724B MX 2019012428 A MX2019012428 A MX 2019012428A MX 2019012428 A MX2019012428 A MX 2019012428A MX 389724 B MX389724 B MX 389724B
- Authority
- MX
- Mexico
- Prior art keywords
- phenyl
- compounds
- acetylamino
- hydroxy
- methyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
- C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17382207 | 2017-04-18 | ||
| PCT/US2018/027005 WO2018194885A1 (en) | 2017-04-18 | 2018-04-11 | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019012428A MX2019012428A (es) | 2022-01-28 |
| MX389724B true MX389724B (es) | 2025-03-20 |
Family
ID=58606227
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019012428A MX389724B (es) | 2017-04-18 | 2018-04-11 | Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo |
| MX2022001310A MX2022001310A (es) | 2017-04-18 | 2019-10-17 | Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022001310A MX2022001310A (es) | 2017-04-18 | 2019-10-17 | Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo. |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US11655214B2 (https=) |
| EP (2) | EP4039675B1 (https=) |
| JP (2) | JP7110232B2 (https=) |
| KR (2) | KR102575246B1 (https=) |
| CN (2) | CN117510405A (https=) |
| AU (2) | AU2018255191B2 (https=) |
| BR (1) | BR112019021867A2 (https=) |
| CO (1) | CO2019012767A2 (https=) |
| CR (1) | CR20190519A (https=) |
| CY (1) | CY1125150T1 (https=) |
| DK (2) | DK4039675T3 (https=) |
| ES (2) | ES2988739T3 (https=) |
| FI (1) | FI4039675T3 (https=) |
| HR (2) | HRP20220263T1 (https=) |
| HU (2) | HUE057745T2 (https=) |
| IL (2) | IL270005B (https=) |
| LT (2) | LT3612519T (https=) |
| MX (2) | MX389724B (https=) |
| MY (1) | MY199442A (https=) |
| NZ (1) | NZ758291A (https=) |
| PH (1) | PH12019502363B1 (https=) |
| PL (2) | PL4039675T3 (https=) |
| PT (2) | PT4039675T (https=) |
| RS (2) | RS65914B1 (https=) |
| SA (1) | SA519410320B1 (https=) |
| SG (1) | SG11201909680UA (https=) |
| SI (2) | SI4039675T1 (https=) |
| SM (2) | SMT202400357T1 (https=) |
| WO (1) | WO2018194885A1 (https=) |
| ZA (1) | ZA201906811B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL4039675T3 (pl) | 2017-04-18 | 2025-01-07 | Eli Lilly And Company | Związki fenylo-2-hydroksyacetyloamino-2-metylo-fenylowe |
| US20210121527A1 (en) * | 2018-03-26 | 2021-04-29 | Icahn School Of Medicine At Mount Sinai | Methods of treating minimal residual cancer |
| EP4021893A1 (en) * | 2019-08-29 | 2022-07-06 | Hibercell, Inc. | Perk inhibiting compounds |
| US20220356186A1 (en) * | 2019-08-29 | 2022-11-10 | Hibercell, Inc. | Perk inhibiting pyrrolopyrimidine compounds |
| WO2021041976A1 (en) | 2019-08-29 | 2021-03-04 | Hibercell, Inc. | Perk inhibiting indolinyl compounds |
| US12331054B2 (en) | 2019-08-29 | 2025-06-17 | Hibercell, Inc. | Perk inhibiting imidazolopyrazine compounds |
| WO2021231788A1 (en) * | 2020-05-13 | 2021-11-18 | Hibercell, Inc. | Perk inhibiting pyrrolopyrimidine compounds to treat viral infections |
| WO2021231782A1 (en) * | 2020-05-13 | 2021-11-18 | Hibercell, Inc. | Perk inhibitors for treating viral infections |
| CN113234029B (zh) * | 2021-05-25 | 2022-03-22 | 白银康寓信生物科技有限公司 | 一种2-氨基-3,5-二卤代吡嗪的合成方法 |
| AU2024242199A1 (en) * | 2023-03-30 | 2025-10-30 | Hibercell, Inc. | Crystalline forms of (r)-2-amino-5-(4-(2-(3,5-difluorophenyl)-2-hydroxyacetamido)-2-methylphenyl)-n-isopropylnicotinamide and methods for using the same |
| GB202407386D0 (en) | 2024-05-24 | 2024-07-10 | Apollo Ap45 Ltd | 1H-pyrazolo(4,3-D)pyrimidine derivatives |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| DK0970084T3 (da) | 1997-03-19 | 2003-09-29 | Abbott Gmbh & Co Kg | Pyrrolo[2,3-d]pyrimidiner og deres anvendelse som inhibitorer for tyrosinkinase |
| US7863444B2 (en) | 1997-03-19 | 2011-01-04 | Abbott Laboratories | 4-aminopyrrolopyrimidines as kinase inhibitors |
| TW200306819A (en) * | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
| EP1501514B1 (en) * | 2002-05-03 | 2012-12-19 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| EA010485B1 (ru) * | 2003-07-23 | 2008-10-30 | Байер Фамэсьютиклс Копэрейшн | Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты) |
| WO2005030933A2 (en) | 2003-09-24 | 2005-04-07 | Genera Doo | Bone morphogenetic protein (bmp)-7 based diagnosis and treatment of cancer |
| PE20070335A1 (es) * | 2005-08-30 | 2007-04-21 | Novartis Ag | Benzimidazoles sustituidos y metodos para su preparacion |
| US8211919B2 (en) * | 2005-09-02 | 2012-07-03 | Astellas Pharma Inc. | Amide derivatives as rock inhibitors |
| NZ617520A (en) | 2008-02-25 | 2015-05-29 | Nestec Sa | Drug selection for breast cancer therapy using antibody-based arrays |
| US20120014911A1 (en) | 2009-01-09 | 2012-01-19 | Serge Fuchs | Regulators of the Interferon-Alpha Receptor 1 (IFNAR1) Chain of the Interferon Receptor |
| CA2794153C (en) | 2010-03-25 | 2018-01-02 | Glaxosmithkline Llc | Substituted indoline derivatives as perk inhibitors |
| EP2986286A1 (en) | 2013-04-15 | 2016-02-24 | Universita' Degli Studi di Bari | Galloyl benzamide-based compounds as jnk modulators |
| WO2015056180A1 (en) | 2013-10-15 | 2015-04-23 | Glaxosmithkline Intellectual Property (No.2) Limited | Indoline derivatives as inhibitors of perk |
| WO2015068767A1 (ja) | 2013-11-08 | 2015-05-14 | 小野薬品工業株式会社 | ピロロピリミジン誘導体 |
| WO2015136463A1 (en) | 2014-03-11 | 2015-09-17 | Glaxosmithkline Intellectual Property (No.2) Limited | Chemical compounds acting as perk inhibitors |
| WO2016004254A1 (en) | 2014-07-01 | 2016-01-07 | The Regents Of The University Of California | Combined modulation of ire1 |
| ES2792036T3 (es) | 2014-11-14 | 2020-11-06 | Nerviano Medical Sciences Srl | Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de cinasa |
| GB201508747D0 (en) | 2015-05-21 | 2015-07-01 | Univ Edinburgh | Compounds |
| WO2017019442A1 (en) * | 2015-07-24 | 2017-02-02 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to kit and pdgfr |
| CN109153680B (zh) | 2016-07-07 | 2021-04-23 | 株式会社大熊制药 | 4-氨基吡唑并[3,4-d]嘧啶基氮杂双环衍生物及含其的药物组合物 |
| JP2019521166A (ja) | 2016-07-20 | 2019-07-25 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｐｅｒｋ阻害剤としてのイソキノリン誘導体 |
| CN106748989B (zh) | 2016-11-14 | 2020-03-17 | 西安交通大学 | 一种具有抗肿瘤活性的二芳基脲类化合物及其制备方法和应用 |
| US20190388426A1 (en) | 2017-01-30 | 2019-12-26 | Université de Liège | Perk and ire-1a inhibitors against neurodevelopmental disorders |
| PL4039675T3 (pl) | 2017-04-18 | 2025-01-07 | Eli Lilly And Company | Związki fenylo-2-hydroksyacetyloamino-2-metylo-fenylowe |
| JP7304855B2 (ja) | 2017-11-14 | 2023-07-07 | ザ チルドレンズ メディカル センター コーポレーション | 新規イミダゾピリミジン化合物およびそれらの使用 |
| EP3492454A1 (en) | 2017-11-30 | 2019-06-05 | Step Pharma S.A.S. | Compounds |
| US20210121527A1 (en) | 2018-03-26 | 2021-04-29 | Icahn School Of Medicine At Mount Sinai | Methods of treating minimal residual cancer |
| US11186579B2 (en) | 2018-07-06 | 2021-11-30 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| US20220040183A1 (en) | 2018-10-01 | 2022-02-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of inhibitors of stress granule formation for targeting the regulation of immune responses |
-
2018
- 2018-04-11 PL PL21211015.9T patent/PL4039675T3/pl unknown
- 2018-04-11 CN CN202310753648.5A patent/CN117510405A/zh active Pending
- 2018-04-11 JP JP2019556703A patent/JP7110232B2/ja active Active
- 2018-04-11 KR KR1020197033523A patent/KR102575246B1/ko active Active
- 2018-04-11 DK DK21211015.9T patent/DK4039675T3/da active
- 2018-04-11 SI SI201831149T patent/SI4039675T1/sl unknown
- 2018-04-11 LT LTEPPCT/US2018/027005T patent/LT3612519T/lt unknown
- 2018-04-11 WO PCT/US2018/027005 patent/WO2018194885A1/en not_active Ceased
- 2018-04-11 PL PL18718570T patent/PL3612519T3/pl unknown
- 2018-04-11 PH PH1/2019/502363A patent/PH12019502363B1/en unknown
- 2018-04-11 HU HUE18718570A patent/HUE057745T2/hu unknown
- 2018-04-11 KR KR1020237029674A patent/KR20230129627A/ko not_active Ceased
- 2018-04-11 SM SM20240357T patent/SMT202400357T1/it unknown
- 2018-04-11 HU HUE21211015A patent/HUE068023T2/hu unknown
- 2018-04-11 EP EP21211015.9A patent/EP4039675B1/en active Active
- 2018-04-11 PT PT212110159T patent/PT4039675T/pt unknown
- 2018-04-11 MX MX2019012428A patent/MX389724B/es unknown
- 2018-04-11 FI FIEP21211015.9T patent/FI4039675T3/fi active
- 2018-04-11 CR CR20190519A patent/CR20190519A/es unknown
- 2018-04-11 US US16/606,410 patent/US11655214B2/en active Active
- 2018-04-11 ES ES21211015T patent/ES2988739T3/es active Active
- 2018-04-11 DK DK18718570.7T patent/DK3612519T3/da active
- 2018-04-11 SG SG11201909680U patent/SG11201909680UA/en unknown
- 2018-04-11 RS RS20240950A patent/RS65914B1/sr unknown
- 2018-04-11 ES ES18718570T patent/ES2906847T3/es active Active
- 2018-04-11 RS RS20220154A patent/RS62933B1/sr unknown
- 2018-04-11 LT LTEP21211015.9T patent/LT4039675T/lt unknown
- 2018-04-11 SI SI201830572T patent/SI3612519T1/sl unknown
- 2018-04-11 HR HRP20220263TT patent/HRP20220263T1/hr unknown
- 2018-04-11 CN CN201880033126.5A patent/CN110831927B/zh active Active
- 2018-04-11 AU AU2018255191A patent/AU2018255191B2/en active Active
- 2018-04-11 BR BR112019021867-0A patent/BR112019021867A2/pt not_active Application Discontinuation
- 2018-04-11 NZ NZ758291A patent/NZ758291A/en unknown
- 2018-04-11 EP EP18718570.7A patent/EP3612519B1/en active Active
- 2018-04-11 HR HRP20241188TT patent/HRP20241188T1/hr unknown
- 2018-04-11 MY MYPI2019006116A patent/MY199442A/en unknown
- 2018-04-11 PT PT187185707T patent/PT3612519T/pt unknown
- 2018-04-11 SM SM20220100T patent/SMT202200100T1/it unknown
-
2019
- 2019-10-16 ZA ZA2019/06811A patent/ZA201906811B/en unknown
- 2019-10-17 IL IL270005A patent/IL270005B/en unknown
- 2019-10-17 MX MX2022001310A patent/MX2022001310A/es unknown
- 2019-10-17 SA SA519410320A patent/SA519410320B1/ar unknown
- 2019-11-15 CO CONC2019/0012767A patent/CO2019012767A2/es unknown
-
2021
- 2021-12-09 IL IL288822A patent/IL288822B2/en unknown
-
2022
- 2022-03-01 CY CY20221100173T patent/CY1125150T1/el unknown
- 2022-07-18 AU AU2022206702A patent/AU2022206702B2/en active Active
- 2022-07-20 JP JP2022115300A patent/JP7331212B2/ja active Active
-
2023
- 2023-04-13 US US18/300,237 patent/US12590064B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA519410320B1 (ar) | مركبات فينيل -2-هيدروكسي-أسيتيل أمينو -2-ميثيل-فينيل | |
| EA201692177A1 (ru) | Соединения и композиции в качестве агонистов toll-подобного рецептора 7 | |
| EA201990912A1 (ru) | Анти-lag-3 антитела и их композиции | |
| EA201692201A1 (ru) | Соединения и композиции в качестве агонистов toll-подобного рецептора 7 | |
| EA201791867A1 (ru) | Бициклические гетероциклы как ингибиторы fgfr4 | |
| GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| EA201691940A1 (ru) | Новые соединения | |
| EA201691857A1 (ru) | Соединения, применимые в качестве иммуномодуляторов | |
| EA201790806A1 (ru) | Иммунорегулирующие средства | |
| EA201792205A1 (ru) | Гетероциклические соединения как ингибиторы lsd1 | |
| PH12015502028A1 (en) | Ido inhibitors | |
| MX373103B (es) | Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1). | |
| MX2016000295A (es) | Inhibidores de indoleamina 2,3-dioxigenasa (ido). | |
| EA201990400A1 (ru) | Соединения и композиции и их применение | |
| MX2020006237A (es) | Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4. | |
| CR20200214A (es) | ALCOHOLES TERCIARIOS COMO INHIBIDORES DE PI3K-y | |
| MX379271B (es) | Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cáncer. | |
| EA202090414A1 (ru) | Соединения и их применение | |
| MX2019001634A (es) | Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos. | |
| EA201890449A1 (ru) | Фумагиллиновые гетероциклические соединения и способы их получения и применения | |
| MX382175B (es) | Composiciones de profármaco de monometilfumarato | |
| MY180844A (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
| EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
| MX381643B (es) | Compuestos heteroarilo bicíclicos sustituidos como agonistas rxr. | |
| PH12017501147A1 (en) | Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs |